132 related articles for article (PubMed ID: 37543274)
1. Discovery of SHR5428 as a selective and noncovalent inhibitor of CDK7.
Jia M; Wang W; Chen G; Wu T; Zhang T; Zhou Q; Yin J; Li J; Li X; Mao Y; Feng J; Hu M; Li X; He F
Bioorg Med Chem Lett; 2023 Sep; 93():129429. PubMed ID: 37543274
[TBL] [Abstract][Full Text] [Related]
2. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
3. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
[TBL] [Abstract][Full Text] [Related]
4. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
Patel H; Periyasamy M; Sava GP; Bondke A; Slafer BW; Kroll SHB; Barbazanges M; Starkey R; Ottaviani S; Harrod A; Aboagye EO; Buluwela L; Fuchter MJ; Barrett AGM; Coombes RC; Ali S
Mol Cancer Ther; 2018 Jun; 17(6):1156-1166. PubMed ID: 29545334
[TBL] [Abstract][Full Text] [Related]
5. Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7.
Marineau JJ; Hamman KB; Hu S; Alnemy S; Mihalich J; Kabro A; Whitmore KM; Winter DK; Roy S; Ciblat S; Ke N; Savinainen A; Wilsily A; Malojcic G; Zahler R; Schmidt D; Bradley MJ; Waters NJ; Chuaqui C
J Med Chem; 2022 Jan; 65(2):1458-1480. PubMed ID: 34726887
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.
Bockstaele L; Bisteau X; Paternot S; Roger PP
Mol Cell Biol; 2009 Aug; 29(15):4188-200. PubMed ID: 19487459
[TBL] [Abstract][Full Text] [Related]
7. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
Olson CM; Liang Y; Leggett A; Park WD; Li L; Mills CE; Elsarrag SZ; Ficarro SB; Zhang T; Düster R; Geyer M; Sim T; Marto JA; Sorger PK; Westover KD; Lin CY; Kwiatkowski N; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):792-803.e10. PubMed ID: 30905681
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
9. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
Kovalová M; Havlíček L; Djukic S; Škerlová J; Peřina M; Pospíšil T; Řezníčková E; Řezáčová P; Jorda R; Kryštof V
Biomed Pharmacother; 2023 May; 161():114492. PubMed ID: 36931035
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
11. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
[TBL] [Abstract][Full Text] [Related]
12. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
[TBL] [Abstract][Full Text] [Related]
13. N76-1, a novel CDK7 inhibitor, exhibits potent anti-cancer effects in triple negative breast cancer.
Zhang L; Wu L; Zhou D; Wang G; Chen B; Shen Z; Li X; Wu Q; Qu N; Wu Y; Yuan L; Gan Z; Zhou W
Eur J Pharmacol; 2023 Sep; 955():175892. PubMed ID: 37429520
[TBL] [Abstract][Full Text] [Related]
14. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
15. Control of Expression of Key Cell Cycle Enzymes Drives Cell Line-Specific Functions of CDK7 in Human PDAC Cells.
Kolloch L; Kreinest T; Meisterernst M; Oeckinghaus A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054996
[TBL] [Abstract][Full Text] [Related]
16. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
[TBL] [Abstract][Full Text] [Related]
17. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.
Larochelle S; Merrick KA; Terret ME; Wohlbold L; Barboza NM; Zhang C; Shokat KM; Jallepalli PV; Fisher RP
Mol Cell; 2007 Mar; 25(6):839-50. PubMed ID: 17386261
[TBL] [Abstract][Full Text] [Related]
18. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
19. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.
Kobayashi M; Takahashi-Suzuki I; Shimomura T; Iwasawa Y; Hirai H
Invest New Drugs; 2011 Oct; 29(5):921-31. PubMed ID: 20524038
[TBL] [Abstract][Full Text] [Related]
20. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
